CLINICAL TRIALS PROFILE FOR PHEBURANE

All Clinical Trials for PHEBURANE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05836350 ↗	Role of BCAA in Glucose Homeostasis	Not yet recruiting	Maastricht University	Phase 4	2023-06-01	This clinical trial study aims to evaluate the effects of prolonged NaPB treatment in a maximum of 20 patients with T2D. The primary objective is: to investigate if prolonged boosting of ing BCAA oxidation will substantially lower plasma glucose levels in patients with T2D. Participants will undergo a Clinical randomized controlled trial (RCT) with a double-blinded, placebo-controlled, cross-over design, including a wash-out period of 12 weeks. The trial will contain 2 treatment arms, with each a duration of 12 weeks. Participants will have a 12-week oral administration of 4.8 g/m2/day NaPB (in the form of Pheburane) or placebo per day. Although depending on body surface area, ~21 g Pheburane needs to be administered spread over the day 3 times taken with a meal.

Clinical Trial Conditions for PHEBURANE

Condition Name

Condition Name for PHEBURANE
Intervention	Trials
Type 2 Diabetes	1

Condition MeSH

Condition MeSH for PHEBURANE
Intervention	Trials
Diabetes Mellitus, Type 2	1

Clinical Trial Progress for PHEBURANE

Clinical Trial Phase

Clinical Trial Phase for PHEBURANE
Clinical Trial Phase	Trials
Phase 4	1

Clinical Trial Status

Clinical Trial Status for PHEBURANE
Clinical Trial Phase	Trials
Not yet recruiting	1

Clinical Trial Sponsors for PHEBURANE

Sponsor Name

Sponsor Name for PHEBURANE
Sponsor	Trials
Maastricht University	1

Sponsor Type

Sponsor Type for PHEBURANE
Sponsor	Trials
Other	1